Introduction：Basic information about CAS 133865-89-1|Safinamide, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Safinamide |
|---|
| CAS Number | 133865-89-1 | Molecular Weight | 302.343 |
|---|
| Density | 1.2±0.1 g/cm3 | Boiling Point | 476.7±40.0 °C at 760 mmHg |
|---|
| Molecular Formula | C17H19FN2O2 | Melting Point | 208-212° |
|---|
| MSDS | / | Flash Point | 242.1±27.3 °C |
|---|
Names
| Name | (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide |
|---|
| Synonym | More Synonyms |
|---|
Safinamide BiologicalActivity
| Description | Safinamide (EMD 1195686; FCE 26743) selectively and reversibly inhibits MAO-B with IC50 of 98 nM, exhibits 5918-fold selectivity against MAO-A.IC50 value: 98 nM [1]Target: MAO-BSafinamide (EMD 1195686; FCE 26743; ) is a highly selective and reversible monoamine oxidase type B (MAO-B) inhibitor that increases neostriatal dopamine concentration. In addition, Safinamide (EMD 1195686; FCE 26743; ) is voltage-dependent sodium and calcium channel blocker. Safinamide (EMD 1195686; FCE 26743; ) appears to bind to the batrachotoxin-sensitive site 2 of the voltage-sensitive sodium channels. Safinamide blocks N and L-type calcium channels and inhibits glutamate and aspartate release from synaptic terminals. |
|---|
| Related Catalog | Signaling Pathways >>Neuronal Signaling >>Monoamine OxidaseResearch Areas >>Neurological Disease |
|---|
| References | [1]. Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50(20), 4909-4916. [2]. Schapira AH. Safinamide in the treatment of Parkinson's disease. Expert Opin Pharmacother. 2010 Sep;11(13):2261-8. [3]. Onofrj M, et al. An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. [4]. Chazot PL. Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome. Curr Opin Investig Drugs. 2007 Jul;8(7):570-9. [5]. Dal Bo L, et al. Bioassay of safinamide in biological fluids of humans and various animal species. Arzneimittelforschung. 2006;56(12):814-9. http://www.ncbi.nlm.nih.gov/pubmed/17260668 |
|---|
Chemical & Physical Properties
| Density | 1.2±0.1 g/cm3 |
|---|
| Boiling Point | 476.7±40.0 °C at 760 mmHg |
|---|
| Melting Point | 208-212° |
|---|
| Molecular Formula | C17H19FN2O2 |
|---|
| Molecular Weight | 302.343 |
|---|
| Flash Point | 242.1±27.3 °C |
|---|
| Exact Mass | 302.143066 |
|---|
| PSA | 64.35000 |
|---|
| LogP | 2.37 |
|---|
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
|---|
| Index of Refraction | 1.570 |
|---|
| InChIKey | NEMGRZFTLSKBAP-LBPRGKRZSA-N |
|---|
| SMILES | CC(NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O |
|---|
Safety Information
| Hazard Codes | Xi |
|---|
| RTECS | TX1457385 |
|---|
Synonyms
| (S)-(+)-2-[4-(3-fluorobenzyloxy)benzylamino]-propanamide |
| (2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide |
| Safinamide |
| N-{4-[(3-Fluorobenzyl)oxy]benzyl}-L-alaninamide |
| (2S)-2-[[[4-[(3-Fluorophenyl)methoxy]phenyl]methyl]amino]propanamide |
| (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propionamide |
| ZVY1&M1R DO1R CF &&L or S Form |
| Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)- |
